INTRODUCTION AND OBJECTIVES: Clear cell renal cell carcinoma (CCC), the main subtype of kidney cancer, represents 250 000 cases and 110 000 deaths worldwide/year. In 75% of cases there is a loss of the von Hippel-Lindau (VHL) tumor suppressor gene that is involved in hypoxia inducible factors (HIF) degradation. Current targeted therapies for advanced CCC arise from the knowledge of the VHL/HIF system. These include sunitinib, sorafenib and everolimus. Their efficiency is however limited due to acquired resistance. Since the classical mechanisms of resistance are not involved in CCC, we hypothesized that signalling pathways and/or markers are involved in such resistance. We focused here on sunitinib.
METHODS: We used a panel of CCC cell lines expressing VHL (Caki-1, Caki-2, ACHN) or not (786-0, A498) and tumor/normal tissues pairs from 50 CCC patients. We analyzed tumor growth in response to sunitinib both in vitro using Cristal Violet assay and in vivo using the xenografted nude mice tumor model (40 mg/kg, 3 times/week, 4 weeks, per os). We analyzed protein expression and signaling pathways by RT-qPCR, Western blot, proteome arrays specific for phosphokinases, apoptosis and angiogenesis and with the HTG EdgeSeq oncology biomarker panel assay (2560 genes of 24 signaling pathways).
RESULTS: In vitro, sunitinib inhibited cell growth of all cell lines tested by up to 85%. In vivo, however, xenografted 786-0 and A498 tumors were resistant to sunitinib. By analyzing A498 tumors we identified, among others, angiogenin (Ang), a pro-angiogenic factor, as being stimulated more than 10 fold by sunitinib. The stimulation of Ang by sunitinib was also observed in all cell lines. Interestingly, in tissue pairs, the expression of Ang was found to be deregulated in 75% of tumors, regardless of tumor stage and grade. Ang stimulates rRNA transcription after nuclear translocation and activates oncogenic signaling pathways (Akt, JunK, MAPK) through a uncharacterized transmembrane receptor. Ang expression and activity has never been functionally linked to sunitinib. In 786-0 tumors-bearing nude mice, tumoral growth was inhibited by 30% by neamine, an inhibitor of Ang nuclear translocation, but it had no effect on sunitinib resistance. Akt and GSK-3 were also activated in vitro and in vivo by sunitinib. We are now performing in vivo studies using siRNA targeting Ang allowing to also inhibit its effect on oncogenic pathways, alone and in combination with sunitinib.
CONCLUSIONS: Taken together, these results strongly suggest that Ang is involved in sunitinib resistance in human CCC, opening new therapeutic option for this refractory disease.
Source of Funding: INSERM, University of Strasbourg

MP73-08 METFORMIN DRIVES SYNERGISTIC EFFECT AND OVERCOMES THE TREATMENT RESISTANCE OF MOLECULAR TARGETED DRUGS FOR RENAL CELL CARCINOMA
Hiroaki Matsumoto*, Juiichi Mori, Kosuke Shimizu, Nakanori Fujii, Yoshihisa Kawai, Ryo Inoue, Yoshiaki Yamamoto, Hiroshi Hirata, Tomoaki Shimabukuro, Hideyasu Matsuyama, Ube, Japan INTRODUCTION AND OBJECTIVES: Molecular targeted drugs have shown clinical benefit and improvement of their QOL for patients with advanced renal cell carcinoma. However, conquest of primary or acquired drug resistance is urgent problem in clinical practice. The previous reports have shown that Metformin is promising treatment approach for several cancers by regulating AMPK-mTOR pathway. In this study, we assessed whether combination of Metformin synergized molecular targeted drugs and repressed the progression of renal cancer model.
METHODS:
We tested synergy effect of Metformin combined with molecular targeted drugs, Everolimus and Axitinib. We assessed cell proliferation and apoptosis by WST-1 assay or a crystal violet assay and flow cytometry. We examined the gene expression profile of parental and molecular targeted drug resistant cells by microarray analysis. And protein expression of the AMPK-mTOR pathway by Western blot. The effects of combination treatment on A498 tumor growth was assessed in orthotropic renal cell carcinoma model. RESULTS: Combination of Metformin + Axitinib showed synergistic effect and more potently suppressed A498 cell growth rates in a dose and time dependent manner compared to Metformin or Axitinib monotherapy. Apoptosis detected by flow cytometry with Annexin V was most enhanced with combination treatment. We compared gene expression profile between parental and Axitinib resistant cell line, several pathways enhanced to survive from cellar stress. Metformin induced AMPK expression and suppressed Akt and mTOR expression in Axitinib treatment. In vivo, combination of Metformin + Axitinib therapy significantly repressed tumor growth compared with their mono therapy. In addition, micro vessel density and VEGF immunostaining were significantly reduced in tumor tissue of combination treatment.
CONCLUSIONS: Metformin showed synergistic effect for renal cell carcinoma growth combined with Axitinib in vitro and in vivo. Combination treatment of Metformin + Axitinib is providing pre-clinical proof-of-principle as a promising approach against drug resistance for renal cell carcinoma.
Source of Funding: Grant-in-Aid for Scientific Research (KAKENHI) 25464281
MP73-09 NELFINAVIR ACTS SYNERGISTICALLY WITH PANOBINOSTAT TO INDUCE ENDOPLASMIC RETICULUM STRESS AND INHIBIT RENAL CANCER GROWTH
Kazuki Okubo*, Akinori Sato, Takako Asano, Makoto Isono, Tomohiko Asano, Tokorozawa, Saitama, Japan INTRODUCTION AND OBJECTIVES: Inducing endoplasmic reticulum (ER) stress is a novel approach to cancer treatment. The pandeacetylase inhibitor panobinostat inhibits molecular chaperones and increases the amount of unfolded proteins. The antiretroviral drug nelfinavir suppresses proteasomes and inhibits degradation of unfolded proteins. We postulated that combining nelfinavir with panobinostat would kill renal cancer cells effectively by inhibiting degradation of panobinostat-increased unfolded proteins and thereby inducing ER stress.
METHODS: After renal cancer cells (769-P, 786-O, Caki-2) were treated with clinically feasible concentrations of panobinostat (15-60 nM) and/or nelfinavir (10-20 mM), their viability and clonogenicity were assessed by MTS assay and colony formation assay. Apoptosis was evaluated by annexin-V assay. Cell cycle analysis was done using flow cytometry. Western blotting was used to evaluate the induction of ER stress (increased expression of ER stress markers) and the expression of cyclin D1, cyclin-dependent kinase (CDK) 4, AMP-activated protein kinase (AMPK), S6 ribosomal protein, and ERK1/2. RESULTS: The combination of panobinostat and nelfinavir was demonstrated by isobologram analysis to inhibit cancer cell growth synergistically. It also suppressed colony formation significantly (p <0.05). The combination decreased the expression of cyclin D1 and CDK4, leading to the accumulation of the cells in the sub-G1 fraction. It also induced robust apoptosis synergistically: 60 nM panobinostat alone caused slight to moderate increases in the amount of annexin-V positive cells but in combination with 20 mM nelfinavir increased it drastically (up to 100-fold). Mechanistically, the combination induced ER stress synergistically. This ER stress caused dephosphorylation of S6 ribosomal protein by increasing the expression of mammalian target of rapamycin (mTOR) inhibitor AMPK, showing that the combination also inhibited the mTOR pathway. The combination also inhibited the ERK pathway.
CONCLUSIONS: The combination of panobinostat and nelfinavir inhibits renal cancer growth by inducing ER stress synergistically. Inhibiting the mTOR and ERK pathways are also important mechanisms of action.
Source of Funding: none e966
THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
